サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1787158

マイクロニードルインフルエンザワクチンの世界市場

Microneedle Flu Vaccine

出版日
ページ情報
英文 265 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.53円
マイクロニードルインフルエンザワクチンの世界市場
出版日: 2025年08月08日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 265 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

マイクロニードルインフルエンザワクチンの世界市場は2030年までに21億米ドルに達する見込み

2024年に15億米ドルと推定されるマイクロニードルインフルエンザワクチンの世界市場は、2024年から2030年にかけてCAGR 5.2%で成長し、2030年には21億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである固体マイクロニードルは、CAGR 6.1％を記録し、分析期間終了までに14億米ドルに達すると予測されています。中空マイクロニードル分野の成長率は、分析期間でCAGR 3.5％と推定されます。

米国市場は4億1,740万米ドルと推定、中国はCAGR8.5％で成長予測

米国のマイクロニードルインフルエンザワクチン市場は、2024年には4億1,740万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを8.5%として、2030年までに4億1,870万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.5%と5.2%と予測されています。欧州では、ドイツがCAGR 3.4%で成長すると予測されています。

世界のマイクロニードルインフルエンザワクチン市場- 主要動向と促進要因まとめ

マイクロニードルインフルエンザワクチンとは何か？

マイクロニードルインフルエンザワクチンは、従来のインフルエンザ予防接種に代わる画期的な方法で、ワクチン投与に痛みのない極細の針を使用します。これらのマイクロニードルは、通常、長さわずか1ミリメートルで、皮膚の最外層を貫通するように設計されており、そこでワクチンを免疫細胞に直接送り込み、免疫反応を誘発します。筋肉や皮下層に深く注射する必要がある従来のインフルエンザ・ワクチンとは異なり、マイクロニードル・ベースのインフルエンザ・ワクチンは皮膚の最外層である表皮に投与されます。この新しい送達方法は、不快感の最小化や患者のコンプライアンス向上など、大きな利点をもたらします。

マイクロニードルインフルエンザワクチンは、表皮層に提示された抗原に特に反応する、身体自身の皮膚免疫系を利用することで機能します。皮膚にはランゲルハンス細胞のような免疫細胞が豊富にあり、免疫反応の開始に重要な役割を果たしています。マイクロニードルは皮膚の外側のバリアを迂回し、従来のニードルよりも効果的にワクチンを送達することができ、その結果、より早く、潜在的に強力な免疫反応をもたらします。さらに、マイクロニードルは小さく、皮下注射針や注射器を使用する必要がないため、侵襲性が低く、小児や注射針恐怖症の患者など、注射針を怖がる患者集団にとって理想的です。

従来のインフルエンザ・ワクチンと同様、マイクロニードルインフルエンザワクチンはインフルエンザ・ウイルスに対する免疫反応を引き起こすように設計されているが、痛みが少なく、使いやすいという利点もあります。研究者たちは、スケーラブルで効率的なワクチン送達システムの必要性がより明らかになるにつれて、インフルエンザだけでなく、COVID-19を含む他のさまざまな疾患に対するワクチン送達におけるマイクロニードルの有効性について研究を続けています。マイクロニードル・ワクチンの魅力は、ワクチン接種プロセスをより簡便にし、威圧感を与えることなく、ワクチン接種率の向上と公衆衛生の改善に貢献できる点にあります。

マイクロニードルインフルエンザワクチン市場を牽引する主要動向とは？

いくつかの主要動向がマイクロニードルインフルエンザワクチン市場の成長を形成しており、技術的、社会的、ヘルスケア上の重要な要因が人気の高まりに寄与しています。最も注目すべき動向の一つは、針を使わないワクチン送達システムに対する需要の高まりです。特に小児やトリパノフォビア（注射針恐怖症）を患う人々の間では、注射針に対する恐怖が依然としてワクチン接種の大きな障壁となっています。公衆衛生キャンペーンが、特にリスクの高い集団におけるインフルエンザワクチン接種の重要性を強調し続ける中、マイクロニードルワクチンのような痛みのない代替ワクチンへの需要が高まっています。これらのシステムは、患者のコンプライアンスを高め、ワクチン接種率を向上させる魅力的なソリューションを提供します。

市場成長のもう一つの原動力は、自己投与治療が重視されるようになっていることです。ヘルスケアシステムがより分散化されたケアモデルへと移行するにつれ、患者は利便性と快適性を提供する在宅ソリューションを求めるようになっています。訓練を受けた医療従事者を必要とせずに自己投与できる可能性のあるマイクロニードルインフルエンザワクチンは、この動向に完全に適合しています。診察や注射を必要としない家庭用インフルエンザワクチンの魅力は、特にヘルスケアへのアクセスが制限される可能性のある地方や十分なサービスを受けていない地域において、全体的なアクセシビリティを向上させることができます。

さらに、マイクロニードル技術の継続的な進歩が、ワクチン送達のためのマイクロニードル使用の拡大に寄与しています。生体分解性マイクロニードルや溶解性マイクロニードルなど、マイクロニードル設計における最近の技術革新は、このプロセスをより安全で効率的なものにしています。これらの新素材は、針の廃棄の必要性をなくし、環境への影響を軽減し、全体的な安全性を向上させています。研究者たちはまた、ワクチン自体の安定性と送達能力の強化にも取り組んでおり、マイクロニードル・インフルエンザワクチンを、集団予防接種キャンペーンにおいてより信頼性が高く、スケーラブルな選択肢としています。

マイクロニードルインフルエンザワクチン市場が直面する課題とは？

マイクロニードルインフルエンザワクチンは、その有望な可能性にもかかわらず、普及の妨げとなるいくつかの課題に直面しています。主な課題の一つは、規制当局の承認プロセスです。ワクチン、特にマイクロニードルのような新しい送達方法で投与されるワクチンには、厳しい規制基準が適用されます。FDAをはじめとする世界の規制機関は、新しいワクチンの安全性と有効性を証明するために大規模な臨床試験を要求しており、マイクロニードル・ワクチンの承認スケジュールは長引く可能性があります。特に、従来のインフルエンザ予防接種に匹敵する有効性を実証するための臨床試験が予想以上に長引いた場合、こうしたシステムの市場投入が遅れる可能性があります。

もう一つの重要な課題は、開発と製造のコストです。マイクロニードルベースのシステムは、患者の快適性や使いやすさの面で大きな利点がある一方で、特殊な設備や材料を必要とするため、従来のワクチンよりも開発コストが高くつきます。例えば、高品質で溶解可能なマイクロニードルの製造には、生体分解性ポリマーのような高度な材料が必要なため、より高いコストがかかる可能性があります。このような追加コストは、最終消費者の価格上昇につながる可能性があり、特に低所得地域におけるマイクロニードルインフルエンザワクチンの普及を制限する可能性があります。

さらに、マイクロニードルワクチンには多くの利点があるが、従来のワクチンと同レベルの免疫防御を提供できるかどうかについては、まだ懸念があります。初期の調査では、マイクロニードルは強固な免疫反応を誘導できることが示唆されているが、特に高齢者や免疫不全者など、インフルエンザの重篤な合併症のリスクが高い人々に対する長期的な有効性を確認するためには、さらなる調査が必要です。マイクロニードルワクチンが従来の注射ワクチンと同様に有効であることを確認することは、より広範な公衆衛生の分野で成功するために不可欠です。

マイクロニードルインフルエンザワクチン市場の主な成長促進要因は？

マイクロニードルインフルエンザワクチン市場の成長は、無痛で自己投与可能なヘルスケアソリューションに対する消費者の需要の増加、マイクロニードル設計の技術的進歩、ワクチンの利用しやすさとコンプライアンス強化のための世界の継続的推進など、いくつかの要因によってもたらされます。特に世界の人口の健康意識が高まり、従来の注射に代わるものを求めるようになるにつれて、針のない、痛みのないソリューションに対するニーズは、最も説得力のある成長要因の一つとなっています。注射針に関連する不安や恐怖を経験する個人にとって、マイクロニードルは安全で使いやすい代替手段を提供し、ワクチン接種率を大幅に高める可能性があります。

市場成長を促進するもう1つの主な要因は、在宅ヘルスケアへの動向です。マイクロニードル・ワクチン、特に自己投与型ワクチンは、臨床環境よりも自宅でワクチンを接種することを好む個人にとって理想的です。この動向は、遠隔医療サービスや在宅治療が大幅に増加したCOVID-19パンデミックによって加速されました。患者やヘルスケアプロバイダーが来院を減らし、ヘルスケアシステムの負担を軽減する方法を模索する中、マイクロニードル・ベースのワクチンは、ワクチン接種率を高めるための実行可能な選択肢となっています。

溶解性マイクロニードルや改良型ワクチン製剤の開発など、マイクロニードル材料の技術的進歩も市場を前進させています。これらの技術革新は、マイクロニードルベースのワクチンの全体的な有効性と安全性を向上させるだけでなく、ワクチン投与に伴う環境への影響を軽減します。マイクロニードル技術がより効率的で費用対効果の高いものになるにつれ、特に従来のワクチン送達システムが物流上の課題に直面している地域において、その採用が拡大すると予想されます。

最後に、世界のインフルエンザの流行とパンデミック対策への世界の注目は、マイクロニードルインフルエンザワクチン市場の重要な成長要因です。インフルエンザの季節が予測不可能になり、新型が出現する可能性があるため、効率的で大規模なワクチン接種キャンペーンは極めて重要です。マイクロニードルワクチンは、特にヘルスケアのインフラが限られている発展途上地域において、迅速かつ効果的にワクチンを供給するための、スケーラブルでコスト効率の高いソリューションを提供します。

結論として、マイクロニードル技術の進歩、痛みを伴わないワクチン接種方法に対する消費者の嗜好の高まり、在宅ヘルスケアソリューションへの世界のシフトが引き続き勢いを増していることから、マイクロニードルインフルエンザワクチン市場は大きな成長を遂げようとしています。より効率的で費用対効果の高いマイクロニードルベースのワクチン開発が進む中、同市場は、ワクチン接種のしやすさ、コンプライアンス、公衆衛生の全体的な成果を改善する上で、世界的に重要な役割を果たすと期待されています。

セグメント

製品タイプ（固形マイクロニードル,中空マイクロニードル）;ワクチンタイプ（4価インフルエンザワクチン, 3価インフルエンザワクチン）

調査対象企業の例

  • AbbVie Inc.
  • AstraZeneca
  • Becton, Dickinson and Company（BD）
  • CSL Limited
  • Debiotech S.A.
  • Eli Lilly and Company
  • FluGen, Inc.
  • Harro Hofliger Verpackungsmaschinen GmbH
  • Innocore Pharmaceuticals
  • Johnson & Johnson
  • LTS Lohmann Therapie-Systeme AG
  • MedImmune
  • Merck & Co., Inc.
  • Microdermics, Inc.
  • Micron Biomedical, Inc.
  • NanoPass Technologies
  • Pfizer Inc.
  • Regeneron Pharmaceuticals
  • Sanofi S.A.
  • TSRL, Inc.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他の欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他のアジア太平洋
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他のラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他の中東
  • アフリカ

第4章 競合

目次
Product Code: MCP32146

Global Microneedle Flu Vaccine Market to Reach US$2.1 Billion by 2030

The global market for Microneedle Flu Vaccine estimated at US$1.5 Billion in the year 2024, is expected to reach US$2.1 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2024-2030. Solid Microneedle, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Hollow Microneedle segment is estimated at 3.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$417.4 Million While China is Forecast to Grow at 8.5% CAGR

The Microneedle Flu Vaccine market in the U.S. is estimated at US$417.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$418.7 Million by the year 2030 trailing a CAGR of 8.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global Microneedle Flu Vaccine Market - Key Trends & Drivers Summarized

What Is the Microneedle Flu Vaccine and How Does It Work?

The microneedle flu vaccine is an innovative alternative to traditional flu shots that leverages the use of tiny, painless needles to administer the vaccine. These microneedles, typically measuring only a fraction of a millimeter in length, are designed to penetrate the outermost layer of the skin, where they deliver the vaccine directly to the immune cells, eliciting an immune response. Unlike conventional flu vaccines, which require a deep injection into the muscle or subcutaneous layer, microneedle-based flu vaccines are administered to the epidermis, the skin’s outermost layer. This novel delivery method offers significant advantages, including minimal discomfort and improved patient compliance.

The microneedle flu vaccine works by using the body's own skin immune system, which is particularly responsive to antigens presented in the epidermal layer. Skin is rich in immune cells like Langerhans cells, which play a crucial role in initiating immune responses. Microneedles are able to bypass the skin’s outer barrier and deliver the vaccine more effectively than traditional needles, resulting in a faster and potentially stronger immune response. Additionally, because microneedles are smaller and do not require the use of hypodermic needles or syringes, they are less invasive, making them ideal for patient populations that may have a fear of needles, such as children or individuals with needle phobia.

As with traditional flu vaccines, the microneedle flu vaccine is designed to provoke an immune response to the influenza virus, but with the added benefits of reduced pain and greater ease of use. Researchers are continuing to study the effectiveness of microneedles in delivering vaccines not only for influenza but for a variety of other diseases, including COVID-19, as the need for scalable, efficient vaccine delivery systems becomes more apparent. The appeal of microneedle vaccines lies in their ability to offer a simpler and less intimidating vaccination process, contributing to higher vaccination rates and improved public health outcomes.

What Are the Key Trends Driving the Microneedle Flu Vaccine Market?

Several key trends are shaping the growth of the microneedle flu vaccine market, with significant technological, social, and healthcare factors contributing to its increasing popularity. One of the most notable trends is the rising demand for needle-free vaccine delivery systems. Fear of needles remains a major barrier to vaccination, especially among children and individuals who suffer from trypanophobia (needle fear). As public health campaigns continue to emphasize the importance of flu vaccination, particularly in high-risk populations, the demand for painless alternatives like microneedle vaccines is growing. These systems offer an attractive solution to boost patient compliance and improve vaccination rates.

Another driving force behind the market’s growth is the increasing emphasis on self-administered treatments. As healthcare systems move toward more decentralized models of care, patients are increasingly seeking at-home solutions that offer convenience and comfort. Microneedle flu vaccines, which can potentially be self-administered without the need for trained healthcare professionals, fit perfectly into this trend. The appeal of a home-use flu vaccine that doesn’t require an office visit or injection can improve overall accessibility, particularly in rural or underserved areas where access to healthcare may be limited.

Moreover, the ongoing advancements in microneedle technology are contributing to the expanding use of microneedles for vaccine delivery. Recent innovations in microneedle design, such as bio-degradable and dissolving microneedles, have made the process even safer and more efficient. These new materials eliminate the need for needle disposal, reducing environmental impact and improving overall safety. Researchers are also working to enhance the stability and delivery capabilities of the vaccine itself, making microneedle flu vaccines a more reliable and scalable option for mass vaccination campaigns.

What Are the Challenges Facing the Microneedle Flu Vaccine Market?

Despite its promising potential, the microneedle flu vaccine faces several challenges that could hinder its widespread adoption. One of the primary challenges is the regulatory approval process. Vaccines, especially those administered through novel delivery methods like microneedles, are subject to stringent regulatory standards. The FDA and other global regulatory bodies require extensive clinical trials to prove the safety and efficacy of new vaccines, and the approval timeline for microneedle vaccines may be lengthy. This could delay the availability of these systems in the market, particularly if clinical trials take longer than expected to demonstrate comparable efficacy to traditional flu shots.

Another key challenge is the cost of development and manufacturing. While microneedle-based systems offer significant benefits in terms of patient comfort and ease of use, they also require specialized equipment and materials, making their development more expensive than traditional vaccines. For example, the production of high-quality, dissolvable microneedles may incur higher costs due to the need for advanced materials like bio-degradable polymers. These additional costs could translate into higher prices for the end consumer, which may limit the widespread adoption of microneedle flu vaccines, particularly in low-income regions.

Furthermore, although microneedle vaccines offer numerous advantages, there are still concerns regarding their ability to provide the same level of immune protection as conventional vaccines. While early studies suggest that microneedles can induce a robust immune response, further research is needed to confirm their long-term effectiveness, especially for populations at high risk of severe flu complications, such as the elderly and immunocompromised individuals. Ensuring that microneedle vaccines are as effective as traditional injectable vaccines is critical to their success in the broader public health landscape.

What Are the Main Growth Drivers for the Microneedle Flu Vaccine Market?

The growth in the microneedle flu vaccine market is driven by several factors, including increasing consumer demand for painless and self-administered healthcare solutions, technological advancements in microneedle design, and the continued global push for enhanced vaccine accessibility and compliance. The need for needle-free, pain-free solutions is one of the most compelling growth drivers, particularly as the global population becomes more health-conscious and seeks alternatives to traditional injections. For individuals who experience anxiety or fear associated with needles, microneedles offer a safe, easy-to-use alternative that could significantly boost vaccination rates.

Another major factor driving market growth is the trend toward home-based healthcare. Microneedle vaccines, particularly those that are self-administered, are ideal for individuals who prefer to receive vaccines at home rather than in a clinical setting. This trend has been accelerated by the COVID-19 pandemic, which saw a significant increase in telehealth services and at-home treatments. As patients and healthcare providers seek ways to reduce in-office visits and ease the burden on healthcare systems, microneedle-based vaccines represent a viable option for increasing vaccination coverage.

Technological advancements in microneedle materials, including the development of dissolving microneedles and enhanced vaccine formulations, are also propelling the market forward. These innovations not only improve the overall effectiveness and safety of microneedle-based vaccines but also reduce the environmental impact associated with vaccine administration. As microneedle technologies become more efficient and cost-effective, their adoption is expected to grow, particularly in regions where traditional vaccine delivery systems face logistical challenges.

Finally, the increasing prevalence of influenza worldwide, along with the global focus on pandemic preparedness, is a significant growth driver for the microneedle flu vaccine market. With flu seasons becoming more unpredictable and the potential for new strains to emerge, efficient, large-scale vaccination campaigns are crucial. Microneedle vaccines offer a scalable, cost-effective solution to deliver vaccines quickly and effectively, particularly in developing regions where healthcare infrastructure may be limited.

In conclusion, the microneedle flu vaccine market is poised for significant growth as advancements in microneedle technology, increasing consumer preference for pain-free vaccination methods, and the global shift toward home-based healthcare solutions continue to gain momentum. With the ongoing development of more efficient, cost-effective microneedle-based vaccines, the market is expected to play a vital role in improving vaccination accessibility, compliance, and overall public health outcomes worldwide.

SCOPE OF STUDY:

The report analyzes the Microneedle Flu Vaccine market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Solid Microneedle, Hollow Microneedle); Vaccine Type (Quadrivalent Flu Vaccine, Trivalent Flu Vaccine)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • AbbVie Inc.
  • AstraZeneca
  • Becton, Dickinson and Company (BD)
  • CSL Limited
  • Debiotech S.A.
  • Eli Lilly and Company
  • FluGen, Inc.
  • Harro Hofliger Verpackungsmaschinen GmbH
  • Innocore Pharmaceuticals
  • Johnson & Johnson
  • LTS Lohmann Therapie-Systeme AG
  • MedImmune
  • Merck & Co., Inc.
  • Microdermics, Inc.
  • Micron Biomedical, Inc.
  • NanoPass Technologies
  • Pfizer Inc.
  • Regeneron Pharmaceuticals
  • Sanofi S.A.
  • TSRL, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Microneedle Flu Vaccine - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Painless Drug Delivery Systems Spurs Adoption of Microneedle Flu Vaccines
    • Growth in Needle-Phobia Among Patients Strengthens Business Case for Microneedle Alternatives
    • Increasing Focus on Self-Administration of Vaccines Expands Addressable Market Opportunity
    • Shift Toward Minimally Invasive Healthcare Solutions Drives Adoption of Microneedle Platforms
    • Technological Advancements in Microneedle Fabrication Techniques Propel Product Innovation
    • Growing Emphasis on Cold Chain Independence Accelerates Demand for Microneedle-Based Vaccines
    • Expansion of Global Immunization Programs Throws the Spotlight on Next-Gen Vaccine Delivery Technologies
    • Rising Government Funding for Pandemic Preparedness Drives Growth in Needle-Free Vaccine Platforms
    • Increasing Investment in Smart Drug Delivery Technologies Spurs Development of Integrated Microneedle Systems
    • Regulatory Support for Novel Vaccine Delivery Methods Strengthens Market Entry Opportunities
    • Favorable Reimbursement Policies in Developed Markets Sustain Growth of Advanced Vaccine Formats
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Microneedle Flu Vaccine Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Microneedle Flu Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Microneedle Flu Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Solid Microneedle by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Solid Microneedle by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Solid Microneedle by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Hollow Microneedle by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Hollow Microneedle by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Hollow Microneedle by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Quadrivalent Flu Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Quadrivalent Flu Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Quadrivalent Flu Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Trivalent Flu Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Trivalent Flu Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Trivalent Flu Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Microneedle Flu Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: USA 15-Year Perspective for Microneedle Flu Vaccine by Product Type - Percentage Breakdown of Value Sales for Solid Microneedle and Hollow Microneedle for the Years 2015, 2025 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Microneedle Flu Vaccine by Vaccine Type - Percentage Breakdown of Value Sales for Quadrivalent Flu Vaccine and Trivalent Flu Vaccine for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: Canada 15-Year Perspective for Microneedle Flu Vaccine by Product Type - Percentage Breakdown of Value Sales for Solid Microneedle and Hollow Microneedle for the Years 2015, 2025 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Microneedle Flu Vaccine by Vaccine Type - Percentage Breakdown of Value Sales for Quadrivalent Flu Vaccine and Trivalent Flu Vaccine for the Years 2015, 2025 & 2030
  • JAPAN
    • Microneedle Flu Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: Japan 15-Year Perspective for Microneedle Flu Vaccine by Product Type - Percentage Breakdown of Value Sales for Solid Microneedle and Hollow Microneedle for the Years 2015, 2025 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Microneedle Flu Vaccine by Vaccine Type - Percentage Breakdown of Value Sales for Quadrivalent Flu Vaccine and Trivalent Flu Vaccine for the Years 2015, 2025 & 2030
  • CHINA
    • Microneedle Flu Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: China 15-Year Perspective for Microneedle Flu Vaccine by Product Type - Percentage Breakdown of Value Sales for Solid Microneedle and Hollow Microneedle for the Years 2015, 2025 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Microneedle Flu Vaccine by Vaccine Type - Percentage Breakdown of Value Sales for Quadrivalent Flu Vaccine and Trivalent Flu Vaccine for the Years 2015, 2025 & 2030
  • EUROPE
    • Microneedle Flu Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Microneedle Flu Vaccine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Europe 15-Year Perspective for Microneedle Flu Vaccine by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Microneedle Flu Vaccine by Product Type - Percentage Breakdown of Value Sales for Solid Microneedle and Hollow Microneedle for the Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Microneedle Flu Vaccine by Vaccine Type - Percentage Breakdown of Value Sales for Quadrivalent Flu Vaccine and Trivalent Flu Vaccine for the Years 2015, 2025 & 2030
  • FRANCE
    • Microneedle Flu Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: France Historic Review for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: France 15-Year Perspective for Microneedle Flu Vaccine by Product Type - Percentage Breakdown of Value Sales for Solid Microneedle and Hollow Microneedle for the Years 2015, 2025 & 2030
    • TABLE 53: France Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Microneedle Flu Vaccine by Vaccine Type - Percentage Breakdown of Value Sales for Quadrivalent Flu Vaccine and Trivalent Flu Vaccine for the Years 2015, 2025 & 2030
  • GERMANY
    • Microneedle Flu Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Germany Historic Review for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Germany 15-Year Perspective for Microneedle Flu Vaccine by Product Type - Percentage Breakdown of Value Sales for Solid Microneedle and Hollow Microneedle for the Years 2015, 2025 & 2030
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Microneedle Flu Vaccine by Vaccine Type - Percentage Breakdown of Value Sales for Quadrivalent Flu Vaccine and Trivalent Flu Vaccine for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Italy Historic Review for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Italy 15-Year Perspective for Microneedle Flu Vaccine by Product Type - Percentage Breakdown of Value Sales for Solid Microneedle and Hollow Microneedle for the Years 2015, 2025 & 2030
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Microneedle Flu Vaccine by Vaccine Type - Percentage Breakdown of Value Sales for Quadrivalent Flu Vaccine and Trivalent Flu Vaccine for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Microneedle Flu Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: UK Historic Review for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: UK 15-Year Perspective for Microneedle Flu Vaccine by Product Type - Percentage Breakdown of Value Sales for Solid Microneedle and Hollow Microneedle for the Years 2015, 2025 & 2030
    • TABLE 71: UK Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Microneedle Flu Vaccine by Vaccine Type - Percentage Breakdown of Value Sales for Quadrivalent Flu Vaccine and Trivalent Flu Vaccine for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 74: Spain Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Spain Historic Review for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Spain 15-Year Perspective for Microneedle Flu Vaccine by Product Type - Percentage Breakdown of Value Sales for Solid Microneedle and Hollow Microneedle for the Years 2015, 2025 & 2030
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Spain 15-Year Perspective for Microneedle Flu Vaccine by Vaccine Type - Percentage Breakdown of Value Sales for Quadrivalent Flu Vaccine and Trivalent Flu Vaccine for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 80: Russia Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Russia Historic Review for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Russia 15-Year Perspective for Microneedle Flu Vaccine by Product Type - Percentage Breakdown of Value Sales for Solid Microneedle and Hollow Microneedle for the Years 2015, 2025 & 2030
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Russia 15-Year Perspective for Microneedle Flu Vaccine by Vaccine Type - Percentage Breakdown of Value Sales for Quadrivalent Flu Vaccine and Trivalent Flu Vaccine for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Rest of Europe 15-Year Perspective for Microneedle Flu Vaccine by Product Type - Percentage Breakdown of Value Sales for Solid Microneedle and Hollow Microneedle for the Years 2015, 2025 & 2030
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for Microneedle Flu Vaccine by Vaccine Type - Percentage Breakdown of Value Sales for Quadrivalent Flu Vaccine and Trivalent Flu Vaccine for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Microneedle Flu Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Microneedle Flu Vaccine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Asia-Pacific 15-Year Perspective for Microneedle Flu Vaccine by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for Microneedle Flu Vaccine by Product Type - Percentage Breakdown of Value Sales for Solid Microneedle and Hollow Microneedle for the Years 2015, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Microneedle Flu Vaccine by Vaccine Type - Percentage Breakdown of Value Sales for Quadrivalent Flu Vaccine and Trivalent Flu Vaccine for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Microneedle Flu Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 101: Australia Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Australia Historic Review for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Australia 15-Year Perspective for Microneedle Flu Vaccine by Product Type - Percentage Breakdown of Value Sales for Solid Microneedle and Hollow Microneedle for the Years 2015, 2025 & 2030
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Australia 15-Year Perspective for Microneedle Flu Vaccine by Vaccine Type - Percentage Breakdown of Value Sales for Quadrivalent Flu Vaccine and Trivalent Flu Vaccine for the Years 2015, 2025 & 2030
  • INDIA
    • Microneedle Flu Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 107: India Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: India Historic Review for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: India 15-Year Perspective for Microneedle Flu Vaccine by Product Type - Percentage Breakdown of Value Sales for Solid Microneedle and Hollow Microneedle for the Years 2015, 2025 & 2030
    • TABLE 110: India Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: India 15-Year Perspective for Microneedle Flu Vaccine by Vaccine Type - Percentage Breakdown of Value Sales for Quadrivalent Flu Vaccine and Trivalent Flu Vaccine for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 113: South Korea Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: South Korea Historic Review for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: South Korea 15-Year Perspective for Microneedle Flu Vaccine by Product Type - Percentage Breakdown of Value Sales for Solid Microneedle and Hollow Microneedle for the Years 2015, 2025 & 2030
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: South Korea 15-Year Perspective for Microneedle Flu Vaccine by Vaccine Type - Percentage Breakdown of Value Sales for Quadrivalent Flu Vaccine and Trivalent Flu Vaccine for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 119: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Rest of Asia-Pacific Historic Review for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Rest of Asia-Pacific 15-Year Perspective for Microneedle Flu Vaccine by Product Type - Percentage Breakdown of Value Sales for Solid Microneedle and Hollow Microneedle for the Years 2015, 2025 & 2030
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 15-Year Perspective for Microneedle Flu Vaccine by Vaccine Type - Percentage Breakdown of Value Sales for Quadrivalent Flu Vaccine and Trivalent Flu Vaccine for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Microneedle Flu Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 125: Latin America Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 126: Latin America Historic Review for Microneedle Flu Vaccine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Latin America 15-Year Perspective for Microneedle Flu Vaccine by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Latin America 15-Year Perspective for Microneedle Flu Vaccine by Product Type - Percentage Breakdown of Value Sales for Solid Microneedle and Hollow Microneedle for the Years 2015, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Microneedle Flu Vaccine by Vaccine Type - Percentage Breakdown of Value Sales for Quadrivalent Flu Vaccine and Trivalent Flu Vaccine for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 134: Argentina Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Argentina Historic Review for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Argentina 15-Year Perspective for Microneedle Flu Vaccine by Product Type - Percentage Breakdown of Value Sales for Solid Microneedle and Hollow Microneedle for the Years 2015, 2025 & 2030
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Argentina 15-Year Perspective for Microneedle Flu Vaccine by Vaccine Type - Percentage Breakdown of Value Sales for Quadrivalent Flu Vaccine and Trivalent Flu Vaccine for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 140: Brazil Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Brazil Historic Review for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Brazil 15-Year Perspective for Microneedle Flu Vaccine by Product Type - Percentage Breakdown of Value Sales for Solid Microneedle and Hollow Microneedle for the Years 2015, 2025 & 2030
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Brazil 15-Year Perspective for Microneedle Flu Vaccine by Vaccine Type - Percentage Breakdown of Value Sales for Quadrivalent Flu Vaccine and Trivalent Flu Vaccine for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 146: Mexico Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Mexico Historic Review for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Mexico 15-Year Perspective for Microneedle Flu Vaccine by Product Type - Percentage Breakdown of Value Sales for Solid Microneedle and Hollow Microneedle for the Years 2015, 2025 & 2030
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Mexico 15-Year Perspective for Microneedle Flu Vaccine by Vaccine Type - Percentage Breakdown of Value Sales for Quadrivalent Flu Vaccine and Trivalent Flu Vaccine for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 152: Rest of Latin America Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Latin America Historic Review for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Rest of Latin America 15-Year Perspective for Microneedle Flu Vaccine by Product Type - Percentage Breakdown of Value Sales for Solid Microneedle and Hollow Microneedle for the Years 2015, 2025 & 2030
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 15-Year Perspective for Microneedle Flu Vaccine by Vaccine Type - Percentage Breakdown of Value Sales for Quadrivalent Flu Vaccine and Trivalent Flu Vaccine for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Microneedle Flu Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 158: Middle East Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 159: Middle East Historic Review for Microneedle Flu Vaccine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Middle East 15-Year Perspective for Microneedle Flu Vaccine by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Middle East 15-Year Perspective for Microneedle Flu Vaccine by Product Type - Percentage Breakdown of Value Sales for Solid Microneedle and Hollow Microneedle for the Years 2015, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Microneedle Flu Vaccine by Vaccine Type - Percentage Breakdown of Value Sales for Quadrivalent Flu Vaccine and Trivalent Flu Vaccine for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 167: Iran Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Iran Historic Review for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Iran 15-Year Perspective for Microneedle Flu Vaccine by Product Type - Percentage Breakdown of Value Sales for Solid Microneedle and Hollow Microneedle for the Years 2015, 2025 & 2030
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Iran 15-Year Perspective for Microneedle Flu Vaccine by Vaccine Type - Percentage Breakdown of Value Sales for Quadrivalent Flu Vaccine and Trivalent Flu Vaccine for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 173: Israel Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Israel Historic Review for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Israel 15-Year Perspective for Microneedle Flu Vaccine by Product Type - Percentage Breakdown of Value Sales for Solid Microneedle and Hollow Microneedle for the Years 2015, 2025 & 2030
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Israel 15-Year Perspective for Microneedle Flu Vaccine by Vaccine Type - Percentage Breakdown of Value Sales for Quadrivalent Flu Vaccine and Trivalent Flu Vaccine for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 179: Saudi Arabia Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Saudi Arabia Historic Review for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Saudi Arabia 15-Year Perspective for Microneedle Flu Vaccine by Product Type - Percentage Breakdown of Value Sales for Solid Microneedle and Hollow Microneedle for the Years 2015, 2025 & 2030
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 15-Year Perspective for Microneedle Flu Vaccine by Vaccine Type - Percentage Breakdown of Value Sales for Quadrivalent Flu Vaccine and Trivalent Flu Vaccine for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 185: UAE Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: UAE Historic Review for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: UAE 15-Year Perspective for Microneedle Flu Vaccine by Product Type - Percentage Breakdown of Value Sales for Solid Microneedle and Hollow Microneedle for the Years 2015, 2025 & 2030
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: UAE 15-Year Perspective for Microneedle Flu Vaccine by Vaccine Type - Percentage Breakdown of Value Sales for Quadrivalent Flu Vaccine and Trivalent Flu Vaccine for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 191: Rest of Middle East Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Middle East Historic Review for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Middle East 15-Year Perspective for Microneedle Flu Vaccine by Product Type - Percentage Breakdown of Value Sales for Solid Microneedle and Hollow Microneedle for the Years 2015, 2025 & 2030
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 15-Year Perspective for Microneedle Flu Vaccine by Vaccine Type - Percentage Breakdown of Value Sales for Quadrivalent Flu Vaccine and Trivalent Flu Vaccine for the Years 2015, 2025 & 2030
  • AFRICA
    • Microneedle Flu Vaccine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 197: Africa Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Africa Historic Review for Microneedle Flu Vaccine by Product Type - Solid Microneedle and Hollow Microneedle Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Africa 15-Year Perspective for Microneedle Flu Vaccine by Product Type - Percentage Breakdown of Value Sales for Solid Microneedle and Hollow Microneedle for the Years 2015, 2025 & 2030
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Microneedle Flu Vaccine by Vaccine Type - Quadrivalent Flu Vaccine and Trivalent Flu Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Africa 15-Year Perspective for Microneedle Flu Vaccine by Vaccine Type - Percentage Breakdown of Value Sales for Quadrivalent Flu Vaccine and Trivalent Flu Vaccine for the Years 2015, 2025 & 2030

IV. COMPETITION